SCHEMBL370819

SCHEMBL370819

COc1ccc(Cn2cc(I)c(C=O)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 1/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
DUSP3 P51452 1/20 0.44
NPC1 O15118 3/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
AADAT Q8N5Z0 1/20 0.43
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
PTGS2 P35354 1/20 0.41
MAPT P10636 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALOX15 P16050 1/20 0.41
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
LMNA P02545 1/20 0.40
CACNA1G O43497 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26106761 0.86 RAB9A (0.50) CMA1RAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL29339707 0.81 MEN1 (0.44) CMA1RAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL370625 0.81 MEN1 (0.44) CMA1RAB9AL3MBTL1NPC1KMT2A
SCHEMBL22346821 0.80 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2L3MBTL1DUSP3NPC1
SCHEMBL21796563 0.79 RAB9A (0.49) CMA1RAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL29300824 0.79 HSP90AA1 (0.47) CMA1RAB9ASMN1; SMN2L3MBTL1DUSP3
SCHEMBL28080862 0.78 MEN1 (0.44) CMA1RAB9ASMN1; SMN2NPC1KMT2A
SCHEMBL369192 0.78 AADAT (0.44) CMA1RAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL370291 0.78 KMT2A (0.46) CMA1RAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL369221 0.77 CACNA1G (0.41) RAB9ASMN1; SMN2L3MBTL1DUSP3NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS MERCK SHARP & DOHME CORP. 2013-09-26 US disclosed
EP-2593277-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2013-05-22 EP disclosed
WO-2012009000-A2 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252944-A1 NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM1, GRM3 CMA1 4844/4885RAB9A 1852/4885SMN1; SMN2 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.